AdAlta

Webinars

Updates

Home

Why Invest

Announcements

Lora

AdAlta and SYNthesis BioVentures have executed a Memorandum of Understanding (MoU) to investigate the formation of a jointly owned entity, to be called AdCella, that, once established, will provide innovative cellular immunotherapies originating in Asia with a pathway to western regulated markets via Australian clinical trials and further enhancement with AdAlta’s i-body® technology. 

As part of AdAlta's stated strategy to expand our clinical stage pipeline with assets that work with our i-body® platform, we have identified a unique and exciting opportunity to bring highly innovative cellular immunotherapies to Australian patients. We are delighted to be working with the SYNBV team: their skills, experience and networks in drug development, capital raising and Asia complement ours and significantly strengthens AdCella’s competitive position. We will be able to implement this exciting strategy much more rapidly and with greater capital efficiency and reduced risk as a result of this collaboration.

SYNThesis BioVentures MoU for cellular immunotherapies

Summary